MS/Neuroimmunology

Clinical Research


fact_group

If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or NeurologyResearchPartners@CUAnschutz.edu

 

 

COMIRB #TitlePrincipal InvestigatorEligibility and InformationAdvertisement

20-1569

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis

Amanda Piquet, MD

Clinical Trials

See Advertisement

20-0705

A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod Therapy (ARTIOS)

Enrique Alvarez, MD, PhD

Clinical Trials

n/a

19-1621

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

John Corboy, MD

Clinical Trials

See Advertisement

19-2420A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (Rpc-1063)Amanda Piquet, MDClinical Trialsn/a

20-2135

A single-arm, prospective, multi-center, study to explore maintained efficacy with ofatumumab therapy in patients with relapsing Multiple Sclerosis who discontinue intravenously delivered anti-CD20 monoclonal antibody (aCD20 mAb) therapy (OLIKOS)

Enrique Alvarez, MD, PhD

Clinical Trials

n/a

20-0454

A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis

Enrique Alvarez, MD, PhD

Clinical Trials

n/a

19-2525

Lipoic Acid for Treatment of Progressive Multiple Sclerosis (LAPMS)

Robert Gross, MD

Clinical Trials

N/A

21-3126

The Evaluation Of Immune Responses To Sars-Cov-2 mRNA Vaccines In Multiple Sclerosis Patients On Ocrelizumab

Amanda Piquet, MD

Clinical Trials

See Advertisement

18-1633

Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)

Enrique Alvarez, MD, PhD

Clinical Trials

N/A

17-1884

Risk Factors in Early Multiple Sclerosis (RISE-MS)

John Corboy, MD

Clinical Trials

See Advertisement

19-0393

Detection and Risk in Early MS (DREAMS)

Teri Schreiner, MD, MPH

N/A

See Advertisement

19-1600

An Observational Study Of Ocrelizumab Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies (VERISMO)

Amanda Piquet, MD

N/A

See Advertisement

20-1000

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)

Enrique Alvarez, MD, PhD

Clinical Trials

N/A

16-0156

Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple Sclerosis (NAPPREMS)

Teri Schreiner, MD, MPH

Clinical Trials

N/A

20-2153

Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes

Tim Vollmer, MD

Clinical Trials

See Advertisement

20-0695

Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility Restriction

Mark Manago, DPT, PhD, PT, NCS

Clinical Trials

See Advertisement

18-0179

Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery

Jeffrey Hebert, PT, PhD

Clinical Trials

See Advertisement

20-1527

Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple Sclerosis

Mark Manago, DPT, PhD, PT, NCS

Clinical Trials

See Advertisement

12-0968

Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological Disorders

Enrique Alvarez, MD, PhD

Clinical Trials

n/a

09-0952

Rocky Mountain MS Center Tissue Bank

John Corboy, MD

Clinical Trials

n/a